Are you Dr. Tu?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 90 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1327 Lake Pointe Pkwy
Sugar Land, TX 77478Phone+1 281-566-1900Fax+1 281-566-1901
Summary
- Dr. Janet Tu, MD is an oncologist in Sugar Land, Texas. She is currently licensed to practice medicine in Texas, Alabama, and Arizona. She is affiliated with St. Luke's Health - Sugar Land Hospital, Houston Methodist Sugar Land Hospital, and Memorial Hermann Sugar Land Hospital.
Education & Training
Baylor College of MedicineFellowship, Hematology and Medical Oncology, 2006 - 2009- Baylor College of MedicineResidency, Internal Medicine, 1999 - 2002
- Baylor College of MedicineClass of 1999
Certifications & Licensure
FL State Medical License 2021 - Present
GA State Medical License 2023 - 2026
AZ State Medical License 2023 - 2025
LA State Medical License 2023 - 2025
MS State Medical License 2023 - 2025
OK State Medical License 2023 - 2025
TN State Medical License 2023 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Publications & Presentations
PubMed
- S1701, A Randomized Phase 2 Trial of Carboplatin-Paclitaxel With and Without Ramucirumab in Patients With Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma.Anne S Tsao, Ming-Hui Hsieh, Marianna Koczywas, Janet Tu, Jonathan Riess
JTO Clinical and Research Reports. 2024-12-01 - A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve-Mutant Metastatic Non-Small Cell Lung...Xiuning Le, Jyoti D Patel, Elaine Shum, Christina Baik, Rachel E Sanborn
Journal of Clinical Oncology. 2024-10-08 - Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy.Sang T Kim, Yanshuo Chu, Mercy Misoi, Maria E Suarez-Almazor, Jean H Tayar
Nature Communications. 2024-07-04
Press Mentions
Coping with Lung Cancer and Heart DiseaseJuly 19th, 2018
Rectal Cancer Survivor: Immunotherapy Saved My LifeJuly 16th, 2018- My B-cell Lymphoma Treatment During PregnancyJune 21st, 2018
- Join now to see all
